LY03020 is a dual serotonin 5-HT<sub>2C</sub> receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease. It is taken orally as a controlled-release formulation. The drug is under development by Luye Pharma Group. As of February 2026, it is in phase 1 clinical trials for both indications. The chemical structure of LY03020 does not yet appear to have been disclosed.